Faroxy ( Oxycodone )
Oxycodone HCL immediate release tablet
Introduction
Faroxy® tablets- manufactured by faran shimi pharmaceutical company -contain oxycodone hydrochloride. Oxycodone belongs to a group of medicines called opioid analgesics. Faroxy® is supplied in 5 mg, 15 mg, 30 mg tablets for oral administration. 10 tablets are packed in a blister and 3 blisters are packaged in one box with a leaflet.Oxycodone is a semisynthetic pure opioid agonist whose principal therapeutic action is analgesia.Other pharmacological effects of oxycodone include anxiolysis, euphoria and feelings of relaxation.These effects are mediated by receptors (notably μ) in the central nervous system, Oxycodone binds to the μ-opioid receptor and activates the μ-opioid receptor, whereas it does not bind to the κ-opioid receptor and does not activate the κ-opioid receptor. Importantly, in human beings, oxycodone behaves as a μ-opioid receptor agonist producing analgesia, Oxycodone does not cause psychotomimetic effects, dysphoria, diuresis, or other effects typical for a κ-opioid agonist.

Indications
Faroxy® tablets are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain (acute pain) where the use of an opioid analgesic is appropriate.Faroxy® appears to offer safe and effective postoperative analgesia, and is a well-accepted and reasonable alternative to standard intravenous opioid analgesics.
Important Information
Dosing
*All doses should be titrated to appropriate effect.Dosing:Adult
Initial: 5 to 15 mg every 4 to 6 hours as needed .
Dosing range: 5 to 30 mg per dose every 4 to 6 hours.
Dosing:Renal Impairment:
CrCl ≥60 mL/minute: do not need to be adjusted.
CrCl <60 mL/minute: doses of 33% to 50% of usual initial dosing have been recommended.
Dosing: Hepatic Impairment:
Initiate therapy at 33% to 50% the usual dosage and titrate carefully.
Dosing:Pediatric Initial:
Infants ≤ 6 months 0.025 to 0.05 mg/kg/dose every 4 to 6 hours as needed.
Infants > 6 months, Children:
Patient weight <50 kg: Initial dose: 0.1 to 0.2 mg/kg/dose every 4 to 6 hours as needed.maximum dose range:5 to 10 mg/ dose.
Patient weight ≥50 kg: Initial dose: 5 to 10 mg every 4 to 6 hours as needed.
maximum dose range: 20 mg/ dose.
Dosing:Renal Impairment: GFR ≥50 mL/minute/1.73 m2: No dosage adjustment required
GFR 10 to 50 mL/minute/1.73 m2: Administer 75% of dose
GFR <10 mL/minute/1.73 m2: Administer 50% of dose
Hemodialysis: Administer 50% of dose posthemodialysis
Peritoneal dialysis: Administer 50% of dose
Dosing: Hepatic Impairment: Initiate therapy at 33% to 50% the usual dosage and titrate carefully.
Administration



Major Interactions(Risk X)
Azelastine (Nasal), Bromperidol, Conivaptan, Eluxadoline, Fusidic Acid (Systemic), Idelalisib, Opioids (mixed agonist/ antagonist), Orphenadrine, Oxomemazine, Paraldehyde, Thalidomide.Pregnancy

Breast-Feeding

Contraindications & Cautions
Contraindications




Warnings/Precautions
Concerns related to adverse effects:




Concurrent drug therapy issues:


Special populations:




Side Effects
Central nervous system: Drowsiness, headache, dizzinessDermatologic: Pruritus
Gastrointestinal: Nausea, constipation, vomiting
Miscellaneous: Fever